Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Loading...

Wednesday, July 7, 2021

Growth hormone cocktail improves hepatopulmonary syndrome secondary to hypopituitarism: A case report

paythelady.612 shared this article with you from Inoreader

World J Clin Cases. 2021 Jun 26;9(18):4852-4858. doi: 10.12998/wjcc.v9.i18.4852.

ABSTRACT

BACKGROUND: Metabolic associated fatty liver disease frequently occurs in patients with hypopituitarism and growth hormone (GH) deficiency. Some patients may develop to hepatopulmonary syndrome (HPS). HPS has a poor prognosis and liver transplantation is regarded as the only approach to cure it.

CASE SUMMARY: A 29-year-old man presented with progressive dyspnea for 1 mo. At the age of 10 years, he was diagnosed with panhypopituitarism associated with pituitary stalk interruption syndrome. Levothyroxine and hydrocortisone were given since then. To achieve ideal height, he received GH treatment for 5 years. The patient had an oxygen saturation of 78% and a partial pressure of arterial oxygen of 37 mmHg with an alveolar-arterial oxygen gradient of 70.2 mmHg. Abdominal ultrasonography showed liver cirrhosis and an enlarged spleen. Perfusion lung scan demonstrated intrapulmonary arteriovenous right-to-left shunt. HPS (very severe) was our primary consideration. His hormonal evaluation revealed GH deficiency and hypogonadotropic hypogonadism when thyroid hormone, cortisol, and desmopressin were administrated. After adding with long-acting recombinant human GH and testosterone for 14 mo, his liver function and hypoxemia were improved and his progressive liver fibrosis was stabilized. He was off the waiting list of liver transplantation.

CONCLUSION: Clinicians should screen HPS patients' anterior pituitary function as early as possible and treat them primarily with GH cocktail accordingly.

PMID:34222458 | PMC:PMC8223853 | DOI:10.12998/wjcc.v9.i18.4852
View on the web
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)